Skip to main content
. 2010 Aug 17;103(7):993–1000. doi: 10.1038/sj.bjc.6605852

Figure 1.

Figure 1

Partial response in a patient with inoperable non-small-cell lung cancer receiving sunitinib 37.5 mg per day and irinotecan. CT scans are shown at baseline (A), after 7 weeks (B) and 6 months (C) on treatment.